(Q42993136)

English

Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis

scientific article published on 10 June 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

liver cirrhosis

0 references

David C. Nickle

11

object named as

David Nickle

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

author name string

Richard J O Barnard

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Carolyn M McHale

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

William Newhard

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Carol A Cheney

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Donald J Graham

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Amy L Himmelberger

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Julie Strizki

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Peggy M T Hwang

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Amber A Rivera

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Jacqueline D Reeves

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Mark J Dinubile

12

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Daria J Hazuda

13

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Niloufar Mobashery

14

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

language of work or name

0 references

publication date

10 June 2013

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

443

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

278-284

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Futility rules for telaprevir combination treatment for patients with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.05.013

7 January 2021

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.05.013

7 January 2021

Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.05.013

7 January 2021

HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.05.013

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.05.013

7 January 2021

Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.05.013

7 January 2021

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.05.013

7 January 2021

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.05.013

7 January 2021

Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.05.013

7 January 2021

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.05.013

7 January 2021

A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.05.013

7 January 2021

A transient cell-based phenotype assay for hepatitis C NS3/4A protease: application to potency determinations of a novel macrocyclic inhibitor against diverse protease sequences isolated from plasma infected with HCV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.05.013

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.05.013

7 January 2021

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.05.013

7 January 2021

Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.05.013

7 January 2021

Resistance to direct antiviral agents in patients with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.05.013

7 January 2021

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.05.013

7 January 2021

Response-guided telaprevir combination treatment for hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.05.013

7 January 2021

NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.05.013

7 January 2021

Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.05.013

7 January 2021

Clinical relevance of HCV antiviral drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.05.013

7 January 2021

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.05.013

7 January 2021

Identifiers

10.1016/J.VIROL.2013.05.013

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42993136&oldid=1975953775"